Stifel Nicolaus Boosts 10x Genomics Price Target to $25

Analysts see upside potential for the biotech company's stock.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Stifel Nicolaus has raised its price target for 10x Genomics (NASDAQ:TXG) from $20 to $25, maintaining a "buy" rating on the stock. The investment firm cites the company's strong performance and growth potential in the advanced genomic analysis market.

Why it matters

10x Genomics is a leading provider of integrated solutions for single-cell and spatial genomics analysis, serving a global customer base in the pharmaceutical, biotechnology, and academic research sectors. The increased price target from Stifel Nicolaus suggests analysts see further upside for the company's stock as it continues to innovate and expand its market presence.

The details

In its research report, Stifel Nicolaus highlighted 10x Genomics' robust product portfolio and growing adoption among researchers. The firm believes the company is well-positioned to capitalize on the increasing demand for advanced genomic analysis tools. The new $25 price target represents a potential upside of 8.46% from the stock's previous closing price.

  • Stifel Nicolaus issued the updated research report and price target on Monday, March 2, 2026.

The players

Stifel Nicolaus

A global wealth management and investment banking firm that provides research coverage and investment recommendations on 10x Genomics.

10x Genomics

A biotechnology company that specializes in advanced genomic analysis solutions, including single-cell and spatial genomics technologies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The increased price target from Stifel Nicolaus reflects analysts' confidence in 10x Genomics' ability to maintain its leadership position in the rapidly evolving genomics analysis market, driven by the company's innovative product offerings and growing customer base.